Charis Charalampous,MD (@xaraklas) 's Twitter Profile
Charis Charalampous,MD

@xaraklas

Medicine Resident, PGY2, Georgetown University Hospital, Washington, DC.

ID: 754065051460534272

calendar_today15-07-2016 21:28:13

391 Tweet

254 Takipçi

1,1K Takip Edilen

Robert Z. Orlowski (@myeloma_doc) 's Twitter Profile Photo

#Myeloma Paper of the Day: Report of a modified Staging System for #Waldenström macroglobulinemia utilizing age, albumin, and LDH that provides a simple, clinically useful, and externally validated prognostic model that reliably predicts prognosis: pubmed.ncbi.nlm.nih.gov/38788183/.

#Myeloma Paper of the Day: Report of a modified Staging System for #Waldenström macroglobulinemia utilizing age, albumin, and LDH that provides a simple, clinically useful, and externally validated prognostic  model that reliably predicts prognosis: pubmed.ncbi.nlm.nih.gov/38788183/.
Blood Cancer Talks (@bloodcancertalk) 's Twitter Profile Photo

Tune in to our new episode on updates in primary myelofibrosis with the MPN legend Dr. Ayalew Tefferi! We discussed navitoclax, pelabresib, & selinexor, along with practical tips on PMF management. tinyurl.com/2muy3b72 👇Check out this clip on trial endpoints in PMF!

Taxiarchis Kourelis (@taxkourel) 's Twitter Profile Photo

Amyloidosis Research Consortium Dr. Jeffrey Zonder Ahmad Masri 2 major RCTs of amyloid-removing moabs (and 1 failed) and not a single protocol biopsy post Rx to actually see what happens in the tissues. A major missed opportunity in my opinion. :-( TTR moabs thankfully are doing this.

Blood Cancer Talks (@bloodcancertalk) 's Twitter Profile Photo

Tune in to our brand new episode on updates in #Myeloma MRD with Ben Derman and Manni Mohyuddin, including a spirited discussion on the recent ODAC meeting! You won't want to miss it! share.transistor.fm/s/b7c0e081

Manni Mohyuddin (@mannimd1) 's Twitter Profile Photo

Our paper on performance of myeloma staging systems just out: nature.com/articles/s4140… Thanks to Sam Rubinstein Vincent Rajkumar Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 for their mentorship/support on this piece. Here is a 🧵on this paper and staging/risk stratification in myeloma 1/ #mmsm

Our paper on performance of myeloma staging systems just out:

nature.com/articles/s4140…

Thanks to <a href="/rubinstein_md/">Sam Rubinstein</a> <a href="/VincentRK/">Vincent Rajkumar</a> <a href="/Rfonsi1/">Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽</a> for their mentorship/support on this piece.

Here is a 🧵on this paper and staging/risk stratification in myeloma

1/

#mmsm
Blood Advances (@bloodadvances) 's Twitter Profile Photo

Daratumumab monotherapy may be an effective and well-tolerated treatment in more than half of patients with refractory AIHA and cold agglutinin disease. ow.ly/3jKl50SfJwu #clinicaltrialsandobservations #immunobiologyandimmunotherapy

Daratumumab monotherapy may be an effective and well-tolerated treatment in more than half of patients with refractory AIHA and cold agglutinin disease. ow.ly/3jKl50SfJwu #clinicaltrialsandobservations #immunobiologyandimmunotherapy
Leonidas Palaiodimos (@leonpalaiodimos) 's Twitter Profile Photo

Μπείτε στη θέση ενός νέου ιατρού που βλέπει αυτήν την απόφαση τη στιγμή που βρίσκεται σε δίλημμα για το αν θα πάει στο εξωτερικό ή θα μείνει στην Ελλάδα με σκοπό να ιδιωτεύσει. Μπείτε στη θέση ενός έμπειρου ιατρού του εξωτερικού που βλέπει αυτήν την απόφαση ενώ βρίσκεται σε

Μπείτε στη θέση ενός νέου ιατρού που βλέπει αυτήν την απόφαση τη στιγμή που βρίσκεται σε δίλημμα για το αν θα πάει στο εξωτερικό ή θα μείνει στην Ελλάδα με σκοπό να ιδιωτεύσει. 

Μπείτε στη θέση ενός έμπειρου ιατρού του εξωτερικού που βλέπει αυτήν την απόφαση ενώ βρίσκεται σε
Balkan Myeloma Study Group (BMSG) (@myelomabmsg) 's Twitter Profile Photo

Proud to share new publication from Balkan Myeloma Study Group (BMSG) with cordial congratulations to Prof Kastritis and all coauthors: tandfonline.com/doi/full/10.10…

Thanos Dimopoulos (@thanosdimop) 's Twitter Profile Photo

Congratulations to Pr Stathis Kastritis for receiving the Robert Kyle award for outstanding contributions in Waldenstrom s Macroglobulinemia!

Congratulations to Pr Stathis Kastritis for receiving the Robert Kyle award for outstanding contributions in Waldenstrom s Macroglobulinemia!
Bruno Paiva (@brunopaiva_unav) 's Twitter Profile Photo

#ASH24 Impressive real-world data from the Greek myeloma group suggesting that sustained MRD negativity for 3 years can guide discontinuation of lenalidomide maintenance, probably except in patients with +2 high risk cytogenetics. #mmsm Thanos Dimopoulos

#ASH24 Impressive real-world data from the Greek myeloma group suggesting that sustained MRD negativity for 3 years can guide discontinuation of lenalidomide maintenance, probably except in patients with +2 high risk cytogenetics. #mmsm 
<a href="/thanosdimop/">Thanos Dimopoulos</a>
Saurabh Zanwar (@zanwarsaurabh) 's Twitter Profile Photo

Slides that you love to see 🤩🤩 👏🏽 Thanos Dimopoulos and colleagues Single arm study, but very reassuring data for the role of stopping Len maintenance. Will be sharing with some of my patients who rightly feel very anxious to stop the drug and continue to bear the adverse effects!

Slides that you love to see 🤩🤩
👏🏽 <a href="/thanosdimop/">Thanos Dimopoulos</a> and colleagues

Single arm study, but very reassuring data for the role of stopping Len maintenance. Will be sharing with some of my patients who rightly feel very anxious to stop the drug and continue to bear the adverse effects!
Saurabh Zanwar (@zanwarsaurabh) 's Twitter Profile Photo

Such a nicely done study in a very difficult space! Congratulations Vincent Rajkumar Thanos Dimopoulos 👏🏽👏🏽👏🏽 Short time from diagnosis to enrollment, detailed progression event data and PFS2/OS so crucial! Finite duration of a safe and well-tolerated drug leading to significant benefit

Such a nicely done study in a very difficult space! Congratulations <a href="/VincentRK/">Vincent Rajkumar</a> <a href="/thanosdimop/">Thanos Dimopoulos</a> 👏🏽👏🏽👏🏽

Short time from diagnosis to enrollment, detailed progression event data and PFS2/OS so crucial! 

Finite duration of a safe and well-tolerated drug leading to significant benefit
Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics (@uoatherapeutics) 's Twitter Profile Photo

Ο Διευθυντής της Θεραπευτικής Κλινικής Καθ. Θάνος Δημόπουλος παρουσίασε σήμερα στο Αμερικανικό Συνέδριο Αιματολογίας στο Σαν Ντιέγκο τα αποτελέσματα της μελέτης Aquila για το ασυμπτωματικό πολλαπλό μυέλωμα. Παράλληλη δημοσίευση στο NEJM! Thanos Dimopoulos nejm.org/doi/full/10.10…

Ο Διευθυντής της Θεραπευτικής Κλινικής Καθ. Θάνος Δημόπουλος παρουσίασε σήμερα στο Αμερικανικό Συνέδριο Αιματολογίας στο Σαν Ντιέγκο τα αποτελέσματα της μελέτης Aquila για το ασυμπτωματικό πολλαπλό μυέλωμα. Παράλληλη δημοσίευση στο NEJM! <a href="/thanosdimop/">Thanos Dimopoulos</a> 

nejm.org/doi/full/10.10…
Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

Aaron Goodman - “Papa Heme” Thanos Dimopoulos NEJM Fractures and renal failure did not happen because we monitored the way we did. And made the active MM diagnosis early. That’s not realistic in the real world. Minority patients in our own country have a hard time getting in for timely appointments.

Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

Aaron Goodman - “Papa Heme” Thanos Dimopoulos NEJM No it does not. You risk worse OS unless there is an RCT that says otherwise. At best you can hypothesize that you may have similar OS with “better active MM” treatment” that you can give in 2024. A gamble I’m not willing to take. Without an RCT of your strategy it’s a hypothesis

Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

Solitary plasmacytoma: Mayo Clinic experience and systematic review and meta-analysis of clinical outcomes ⁦Blood Advances⁩ ⁦Mayo Clinic Comprehensive Cancer Center⁩ #OpenAccess ashpublications.org/bloodadvances/…

Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

Solitary plasmacytoma. One lesion, but 3 possible entities with differing prognosis in the differential diagnosis. Outcomes and management. ⁦Mayo Myeloma⁩ ⁦Blood Advances⁩ ⁦ASH⁩ ashpublications.org/bloodadvances/…

Conrad Fischer (@seefisch) 's Twitter Profile Photo

Dear Secretary Marco Rubio thank you for opening J1 visas for doctors and prioritizing them to get them here for July 1. This will make a stronger and healthier America. We appreciate it.